Healthy Life Area Participant

General Media Partner

Media Partners

Novartis Group Russia

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at

Natalia Kolerova

Country President of Novartis Group Russia General Manager of the Novartis Oncology in Russia, Ukraine and CIS countries

Natalia Kolerova was appointed Country President of Novartis Group Russia in September 2019

Natalia joined Novartis in 2008 as the Head of the Specialties Business unit. Subsequently, Natalia served as the Head of the Market Access function and was responsible for ensuring the availability of drugs in the oncological portfolio of the company.

Prior to joining Novartis, Natalia held senior positions in Abbott Lababorats (Abbott Lab SA) and Sanofi-Aventis (Sanofi-Aventis).

Natalia graduated from the I.M. Sechenov First Moscow State Medical University majoring in Pharmacy, as well as Lomonosov Moscow State University, majoring in Sociology. Natalia also holds a MBA degree.


AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on TwitterFacebookInstagramYouTube and LinkedIn.

Antony Wong

Regional Vice-President Russia & CIS AbbVie

Anthony Wong is Regional Vice President for AbbVie’s business in Russia and the CIS region. From 2008, until AbbVie’s spin off from Abbott in 2012, Anthony was the General Manager of the Pharmaceutical Division of Abbott in Russia.

 Anthony has over 20 years’ experience in the pharmaceutical industry, having previously held positions in manufacturing, finance and general management. Before his roles in Abbott and AbbVie, Anthony served as General Manager for Schering Plough for 8 years and 5 years as a Manager at PricewaterhouseCoopers in M&A and Strategic Advisory Services in Russia.

 Anthony’s experience includes 20 years of General Management experience for three Fortune-500 pharmaceutical companies.

 For the past 7 years, Anthony has served on the Board of AIPM, the Association of International Pharmaceutical Companies.

 Anthony earned his B.S. Degree in Industrial Engineering from Columbia University and his MBA in Finance and International Business from New York University.


GSK is a science-led global healthcare company with a special purpose – to help people do more, feel better, live longer. Being headquartered in the UK GSK operates in more than 150 countries and has 3 global businesses that discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Around 100 000 employees work for GSK around the world with more than 16,000 people working in R&D.

 More than 100 GSK prescription drugs are registered in Russia, which are used for the treatment of respiratory diseases, infectious diseases, including HIV infection, diseases of the central nervous system, as well as in the field of urology, immunology, rheumatology, dermatology and in vaccine procurement. GSK is one of the industry leaders in terms of investment in R&D in Russia.

Sean Reilly

VP & General Manager

Sean Reilly joined GSK Pharma Russia as VP & General Manager on August 1, 2020. Sean reports to Luis Arosemena, SVP Emerging Markets Global Pharma Executive, and leads Russia`s RLT team.

In his role, Sean is responsible for leading Russia's growth agenda across CEP, Respiratory, HIV, Vaccines, and Oncology. He will continue working on "Firebird", Russia accelerated development program, which aims to triple GSK business growth in Russia.

Sean was born in Ireland.

At 22 he moved to Colombia and began working in the pharmaceutical industry as a Medical representative. Later Sean held various positions in sales and marketing. Having worked for GSK for 24 years, Sean has strong experience and expertise in pharmaceutical industry. 14 years ago he was appointed to the position of General Manager GSK Colombia.

Before moving to Moscow, Sean held position of General director GSK Mexico.

Sean is married with two children.


Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to

Niels Hessmann

Senior Bayer Representative in Russia & CIS, Managing Director Bayer JSC, Country Division Head Pharmaceuticals Russia/CIS

Niels Hessmann was born in Belgium and studied economics at the University of Antwerp (Belgium). Mr. Hessmann began his career at Schering in 1992 as Market Research Manager (later the company was merged by Bayer).

Since 1996, he headed the marketing and sales department at Schering in Romania and Moldova. In 1999, he took over as CEO of Schering in Kazakhstan, and was responsible for the development of the company in Central Asia.

In 2001, he was appointed as CEO of Schering in Greece, and in 2007 he started his assignment in the Netherlands, where he served as General Representative of Bayer HealthCare. During this period, Mr. Hessmann was responsible for the integration of Bayer with Schering. From November 2011 to February 2015, he was CEO and General Representative of Bayer HealthCare in South Korea.

In March 2015, Niels Hessmann joined Bayer AO.


At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Katerina Pogodina

Managing Director Russia & CIS, Janssen, pharmaceutical division of Johnson & Johnson, Director General Johnson & Johnson LLC

Started her career with Johnson & Johnson back in 2001. Throughout her 19-year career in the company, Katerina held various positions of increasing level of responsibility in sales, marketing, quality and market access departments, and consistently demonstrated integrity and strong results. Katerina has been a member of Janssen Russia board of directors since 2010 and was appointed Country Manager Russia in 2015; she was promoted to the position of Managing Director Janssen Russia & CIS in 2017. In April 2019 she was appointed Director General Johnson & Johnson LLC.

Novo Nordisk LLC

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,500 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit, Facebook, Twitter, LinkedIn, YouTube.

Hans Duijf

Vice President & General Manager, Novo Nordisk Russia & Belarus

Hans Duijf has been appointed as Vice President and General Manager of Novo Nordisk in Russia and Belarus in September 2017.

Mr. Duijf has an extensive and diverse experience of working in Novo Nordisk headquarters and regional branches in Europe, South-East Asia and Latin America. Mr. Duijf began his career within Novo Nordisk more than 20 years ago in sales and marketing. Over the years Mr. Duijf proved himself as an effective manager in positions such as Marketing Director, Business development Director, General Director and Vice President.



Maxim Kuznetsov

Market Leader Philips Central Eastern Europe & Russia, Senior Vice president

Maxim Kuznetsov has been appointed Market Leader Philips Central Eastern Europe & Russia (CEER) in January 2021. In this role, Maxim is responsible for managing the market consisting of 30 countries including Poland, Czech Republic and Romania with the team of over 1 600 employees. He also holds a position of Head of Philips Research Russia Labs in Skolkovo.

Maxim started his career in Electrolux and joined Philips in 2005. Over the last 16 years, he held various sales, marketing and market management positions. In 2012, he was appointed General Manager & Commercial Leader Consumer Lifestyle of Philips Ukraine. In 2014, he became Sector Market Leader Philips Consumer Business Russia and the CIS. In 2017, he took over the role of Market Leader RCA being responsible for business in Russia, CIS countries and Philips Innovation Labs “Skolkovo”.

Under Maxim’s leadership Philips healthcare business grows and develops. With his direct involvement, innovative medical products appeared on the markets of Russia and the CIS. Under the leadership of Maxim Philips official online store for healthcare products has been launched in Russia, as well as new business models have been developed including healthcare consulting, direct contracts for medical equipment supply, public-private partnerships, and medical technology services (MTS) deals. Moreover, a strong focus was put by Maxim on the further development of locally relevant products and solutions for Russia.

Maxim is directly involved in the development of scientific research in Philips, thanks to which Philips Research Russia Labs in Skolkovo keeps launching new projects. The lab scientists focus on the AI-based computer vision technologies for medical image processing and analysis. On top of this, the lab is working on solutions for Radiology workflow optimization and building clinical decision support systems.

Philips has also made significant progress in the promotion and sales of consumer devices. Maxim was involved in the introduction of new Philips consumer products as well in the launch of Philips official online store, which allowed to expand the products distribution system in the region.

Maxim is the Chairperson of the Board of Directors of International Medical Device Manufacturers Association (IMEDA) and a member of the Association of European Business. The association represents and defends the interests of its members in front of state authorities and officials within the healthcare system.

Maxim was born in Saint Petersburg. He graduated from University of Russian Academy of Education, Faculty of Economics and Business in 2000. He received training on leadership development program at Ashridge Business School (London) and Strategic Management and Leadership Executive MBA program. Maxim obtained his Master in Management degree at the Russian Presidential Academy of National Economy and Public Administration.

Maxim is married and brings up three children. In his free time he enjoys fishing and skiing, playing volleyball and snorkeling.


Since 2013, MyGenetics has been creating personal recommendations for maintaining human health based on DNA analysis.

Each client receives a glossy booklet with DNA research results. It contains recommendations on nutrition, caffeine and alcohol metabolism, addiction tendencies, recommended levels of physical activity, and vitamin absorption level.

The advantage of MyGenetics is the ability to convey complex scientific information in a simple and plain language. Genetic scientists, molecular biologists, nutritionists, cosmetologists and anti-age specialists of the Novosibirsk Science Campus are working on the creation of recommendations. After DNA testing, MyGenetics clients receive a personal online consultation with the company's experts who help them understand the details of the report, adjust their lifestyle and answer all questions.

Private clients and medical centers, private practitioners, fitness centers, companies developing wellbeing projects are all using the MyGenetics services.

Vladimir Volobuev

Director of MyGenetics, techpreneur

Since 2014, he has been the head of MyGenetics biotech project, one of the leaders in the direct-to-consumer segment of the Russian DNA testing market. It is a platform for personalization of goods and services based on DNA analysis for Foodtech, FMCG, dietary supplements and the insurance market. It is one of the TOP-500 most promising projects on the planet. Several dozen international partners in more than 30 countries around the world.

2012 - 2013 Managing Director of Sigma Nanocenter (RUSNANO). Main responsibilities: search, examination and launch of technological projects. Transfer and commercialization of technologies.

2006 - 2009 Asset manager at MDM Bank OJSC. Main responsibilities: structure and support of mergers and acquisitions, project finance. 


Higher School of Economics affiliated to the Government of the Russian Federation, Master's program in Corporate Finance

Duisenberg School of finance (Amsterdam), "Venture Investments"